| http://dbpedia.org/ontology/abstract
|
Le reslizumab, commercialisé sous le nom d … Le reslizumab, commercialisé sous le nom de Cinqaero, est un anticorps monoclonal humanisé (IgG4, κ) dirigé contre l'interleukine 5 (IL-5) humaine. Il se lie spécifiquement à l'IL-5 et interfère avec la liaison de l'IL-5 à son récepteur de surface cellulaire et bloque ainsi sa fonction biologique, ce qui a pour conséquence de réduire la survie et l'activité des éosinophiles. la survie et l'activité des éosinophiles.
, Reslizumab (łac. reslizumabum) – humanizowane przeciwciało monoklonalne klasy IgG4/к, wytwarzane metodą inżynierii genetycznej w komórkach szpiczaka mysiego (NS0), stosowane w leczeniu astmy oskrzelowej.
, Reslizumab (Handelsname: Cinqaero von Teva … Reslizumab (Handelsname: Cinqaero von Teva Pharmaceutical Industries) ist ein humanisierter monoklonaler Antikörper zur Behandlung von Asthma bronchiale. Reslizumab bindet spezifisch an das humane Interleukin-5 (IL-5) und stört die Bindung von IL-5 an dessen Zelloberflächenrezeptor.on IL-5 an dessen Zelloberflächenrezeptor.
, Реслизумаб — лекарственный препарат, монок … Реслизумаб — лекарственный препарат, моноклональное антитело для лечения бронхиальной астмы. Одобрен для применения: ЕС, США (2016) 23 марта 2016 года FDA одобрило реслизумаб для использования с другими лекарствами от астмы для поддерживающего лечения тяжелой астмы у пациентов в возрасте 18 лет и старше. Реслизумаб одобрен для пациентов, у которых в анамнезе имеются тяжелые приступы астмы, несмотря на приём текущих лекарств от астмы. 23 июня 2016 года Европейское агентство лекарственных средств рекомендовало выдать разрешение на применение реслизумаба, предназначенного для дополнительного лечения взрослых пациентов с тяжелой эозинофильной астмой. пациентов с тяжелой эозинофильной астмой.
, Reslizumab is a humanized monoclonal antib … Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions. The FDA approved reslizumab (US trade name Cinqair) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older on 23 March 2016. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. The European Medicines Agency recommended the granting of a marketing authorisation for reslizumab (EU trade name Cinqaero) intended as add-on treatment in adult patients with severe eosinophilic asthma on 23 June 2016. Reslizumab is supplied as a refrigerated, sterile, single-use, preservative-free solution for intravenous infusion. The reslizumab solution is a slightly hazy/opalescent, slightly yellow liquid and is supplied as 100 mg in a 10 mL glass vial. Each single-use vial of reslizumab is formulated as 10 mg/mL reslizumab in an aqueous solution containing 2.45 mg/mL sodium acetate trihydrate, 0.12 mg/mL glacial acetic acid, and 70 mg/mL sucrose, with a pH of 5.5.d, and 70 mg/mL sucrose, with a pH of 5.5.
|
| http://dbpedia.org/ontology/alternativeName
|
Cinqair (US), Cinqaero (EU)
|
| http://dbpedia.org/ontology/casNumber
|
241473-69-8
|
| http://dbpedia.org/ontology/drugbank
|
DB06602
|
| http://dbpedia.org/ontology/fdaUniiCode
|
35A26E427H
|
| http://dbpedia.org/ontology/kegg
|
D08985
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/reslizumab +
|
| http://dbpedia.org/ontology/wikiPageID
|
9134258
|
| http://dbpedia.org/ontology/wikiPageLength
|
12012
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1063130779
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Pharmacokinetics +
, http://dbpedia.org/resource/Proteolysis +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Microlitre +
, http://dbpedia.org/resource/Cephalon +
, http://dbpedia.org/resource/Peptide +
, http://dbpedia.org/resource/Volume_of_distribution +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Intravenous +
, http://dbpedia.org/resource/Eosinophilic_asthma +
, http://dbpedia.org/resource/Ception_Therapeutics +
, http://dbpedia.org/resource/Teva_Pharmaceuticals +
, http://dbpedia.org/resource/Placebo +
, http://dbpedia.org/resource/Amino_acid +
, http://dbpedia.org/resource/Sucrose +
, http://dbpedia.org/resource/Myalgia +
, http://dbpedia.org/resource/Eosinophil +
, http://dbpedia.org/resource/Category:Antiasthmatic_drugs +
, http://dbpedia.org/resource/Schering-Plough +
, http://dbpedia.org/resource/Exacerbation +
, http://dbpedia.org/resource/Anaphylactic_reactions +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/FDA +
, http://dbpedia.org/resource/Sputum +
, http://dbpedia.org/resource/Malignancy +
, http://dbpedia.org/resource/Oropharyngeal +
, http://dbpedia.org/resource/Creatine_phosphokinase +
, http://dbpedia.org/resource/Picomolar +
, http://dbpedia.org/resource/Cytokine +
, http://dbpedia.org/resource/Humanized_monoclonal_antibody +
, http://dbpedia.org/resource/Interleukin_5 +
|
| http://dbpedia.org/property/atcPrefix
|
R03
|
| http://dbpedia.org/property/atcSuffix
|
DX08
|
| http://dbpedia.org/property/casNumber
|
241473
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/dailymedid
|
Reslizumab
|
| http://dbpedia.org/property/drugbank
|
DB06602
|
| http://dbpedia.org/property/eliminationHalfLife
|
2073600.0
|
| http://dbpedia.org/property/kegg
|
D08985
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/licenceEu
|
yes
|
| http://dbpedia.org/property/licenceUs
|
Reslizumab
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/metabolism
|
http://dbpedia.org/resource/Proteolysis +
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intravenous +
|
| http://dbpedia.org/property/source
|
zu/a
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/Interleukin_5 +
|
| http://dbpedia.org/property/tradename
|
Cinqair , Cinqaero
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
35
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
464381171
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Immunosuppressants +
, http://dbpedia.org/resource/Template:Empty_section +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Interleukin_receptor_modulators +
, http://dbpedia.org/resource/Template:Monoclonals_for_immune_system +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Keggcite +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Antiasthmatic_drugs +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Reslizumab?oldid=1063130779&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Reslizumab +
|
| owl:sameAs |
http://yago-knowledge.org/resource/Reslizumab +
, http://ru.dbpedia.org/resource/%D0%A0%D0%B5%D1%81%D0%BB%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1 +
, http://pl.dbpedia.org/resource/Reslizumab +
, http://rdf.freebase.com/ns/m.027yyxw +
, http://www.wikidata.org/entity/Q7315650 +
, http://fr.dbpedia.org/resource/Reslizumab +
, http://vi.dbpedia.org/resource/Reslizumab +
, http://dbpedia.org/resource/Reslizumab +
, https://global.dbpedia.org/id/4tdrP +
, http://de.dbpedia.org/resource/Reslizumab +
|
| rdf:type |
http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
|
| rdfs:comment |
Реслизумаб — лекарственный препарат, монок … Реслизумаб — лекарственный препарат, моноклональное антитело для лечения бронхиальной астмы. Одобрен для применения: ЕС, США (2016) 23 марта 2016 года FDA одобрило реслизумаб для использования с другими лекарствами от астмы для поддерживающего лечения тяжелой астмы у пациентов в возрасте 18 лет и старше. Реслизумаб одобрен для пациентов, у которых в анамнезе имеются тяжелые приступы астмы, несмотря на приём текущих лекарств от астмы.смотря на приём текущих лекарств от астмы.
, Reslizumab (łac. reslizumabum) – humanizowane przeciwciało monoklonalne klasy IgG4/к, wytwarzane metodą inżynierii genetycznej w komórkach szpiczaka mysiego (NS0), stosowane w leczeniu astmy oskrzelowej.
, Reslizumab (Handelsname: Cinqaero von Teva … Reslizumab (Handelsname: Cinqaero von Teva Pharmaceutical Industries) ist ein humanisierter monoklonaler Antikörper zur Behandlung von Asthma bronchiale. Reslizumab bindet spezifisch an das humane Interleukin-5 (IL-5) und stört die Bindung von IL-5 an dessen Zelloberflächenrezeptor.on IL-5 an dessen Zelloberflächenrezeptor.
, Reslizumab is a humanized monoclonal antib … Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.inase, myalgia and anaphylactic reactions.
, Le reslizumab, commercialisé sous le nom d … Le reslizumab, commercialisé sous le nom de Cinqaero, est un anticorps monoclonal humanisé (IgG4, κ) dirigé contre l'interleukine 5 (IL-5) humaine. Il se lie spécifiquement à l'IL-5 et interfère avec la liaison de l'IL-5 à son récepteur de surface cellulaire et bloque ainsi sa fonction biologique, ce qui a pour conséquence de réduire la survie et l'activité des éosinophiles. la survie et l'activité des éosinophiles.
|
| rdfs:label |
Reslizumab
, Реслизумаб
|
